Eisai Yönetim

Yönetim kriter kontrolleri 3/4

Eisai CEO'su Haruo Naito, Jun2003 tarihinde atandı, in görev süresi 23.08 yıldır. in toplam yıllık tazminatı ¥ 252.00M olup, şirket hissesi ve opsiyonları dahil olmak üzere 41.3% maaş ve 58.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.23% ine doğrudan sahiptir ve bu hisseler € 15.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 2.6 yıldır.

Anahtar bilgiler

Haruo Naito

İcra Kurulu Başkanı

JP¥252.0m

Toplam tazminat

CEO maaş yüzdesi	41.27%
CEO görev süresi	23.1yrs
CEO sahipliği	0.2%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	2.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Haruo Naito'un ücretlendirmesi Eisai'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	JP¥252m	JP¥104m	JP¥39b
Dec 31 2025	n/a	n/a	JP¥43b
Sep 30 2025	n/a	n/a	JP¥49b
Jun 30 2025	n/a	n/a	JP¥50b
Mar 31 2025	JP¥221m	JP¥104m	JP¥46b
Dec 31 2024	n/a	n/a	JP¥59b
Sep 30 2024	n/a	n/a	JP¥41b
Jun 30 2024	n/a	n/a	JP¥33b
Mar 31 2024	JP¥211m	n/a	JP¥42b
Dec 31 2023	n/a	n/a	JP¥45b
Sep 30 2023	n/a	n/a	JP¥48b
Jun 30 2023	n/a	n/a	JP¥49b
Mar 31 2023	JP¥157m	n/a	JP¥55b
Dec 31 2022	n/a	n/a	JP¥27b
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b

Tazminat ve Piyasa: Haruo 'nin toplam tazminatı ($USD 1.56M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.74M ).

Tazminat ve Kazançlar: Haruo 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Haruo Naito (79 yo)

23.1yrs

Görev süresi

JP¥252,000,000

Tazminat

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Haruo Naito	CEO, Representative Corporate Officer & Director	23.1yrs	JP¥252.00m	0.23% € 15.3m
Keisuke Naito	Representative Corporate Officer	2.1yrs	JP¥124.00m	Veri yok
Terushige Iike	Executive VP	no data	JP¥119.00m	Veri yok
Lynn D. Kramer	VP & Chief Clinical Officer	no data	JP¥310.00m	Veri yok
Yanhui Feng	Senior Vice President	6.5yrs	JP¥203.00m	Veri yok
Takuya Oyama	Vice President	no data	Veri yok	Veri yok
Akiko Nakahama	Vice President of Japan Regulatory Affairs	1.3yrs	Veri yok	Veri yok
Makoto Hoketsu	VP & Chief Information Officer	2.8yrs	Veri yok	Veri yok
Katsutoshi Ido	VP, Chief Scientific Officer & Head of DHBL Discoverry	1.3yrs	Veri yok	Veri yok
Teruyuki Masaka	VP and Chief HR Officer	4.5yrs	Veri yok	Veri yok
Tatsuyuki Yasuno	Senior VP & President of Americas Region	3.5yrs	Veri yok	Veri yok
Shohei Kanazawa	VP & President of East Asia Global South Region API Solutions	9.1yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: EII 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Haruo Naito	CEO, Representative Corporate Officer & Director	12.1yrs	JP¥252.00m	0.23% € 15.3m
Yuko Yasuda	Outside Independent Director	3.1yrs	Veri yok	0.000060% € 3.9k
Fumihiko Ike	Independent Outside Chairman	5.1yrs	Veri yok	0.00035% € 22.8k
Yasushi Okada	Director	1.1yrs	JP¥108.00m	0.011% € 711.2k
Toru Moriyama	Outside Independent Director	3.1yrs	Veri yok	0.00050% € 32.5k
Koichi Kawana	Outside Independent Director	less than a year	Veri yok	Veri yok
Kenta Takahashi	Director	2.1yrs	Veri yok	0.0039% € 255.7k
Hiroyuki Kato	Director	4.1yrs	Veri yok	0.0030% € 195.2k
Ryoko Ueda	Outside Independent Director	1.1yrs	Veri yok	0.000040% € 2.6k
Richard Thornley	Outside Independent Director	4.1yrs	Veri yok	Veri yok
Yuko Toyoda	Outside Independent Director	less than a year	Veri yok	Veri yok
Takuji Kanai	Independent Outside Director	2.1yrs	Veri yok	Veri yok

2.6yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EII 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/07/06 04:10
Gün Sonu Hisse Fiyatı	2026/07/03 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Eisai Co., Ltd. 20 Bu analistlerden 13, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Eisai Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2026

Eisai Co., Ltd., Annual General Meeting, Jun 18, 2025

High number of new directors

Recent updates

Eisai Co., Ltd.'s Acceptance of Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant for Evaluation by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)

Eisai Co Ltd Showcases Alzheimer’s Disease Portfolio With Over 50 Presentations At Alzheimer’s Association International Conference 2026

Nuvation Bio Validates Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer in the United Kingdom

Eisai Co., Ltd. Provides Earnings Guidance for the Fiscal Year 2026 (April 2026 to March 2027)

High number of new directors

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2026

Eisai Co., Ltd. and Biogen Inc. Update on Fda Priority Review of Leqembi Iqlik (Lecanemab-Irmb) Subcutaneous Injection as A Starting Dose for Early Alzheimer's Disease

Eisai Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026

Eisai Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026

Eisai Co., Ltd. and MSD K.K. Submit Application for Lenvima in Combination with Welireg for Renal Cell Carcinoma in Japan

Eisai Co., Ltd. and Nuvation Bio Inc. Announce Marketing Authorisation Application for Taletrectinib for Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab

Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States

Eisai Co., Ltd. Announces Orphan Drug Designation for E2086, a Novel Selective Orexin 2 Receptor Agonist for Narcolepsy

Eisai Announces Leqembi® Iqlik™ (Lecanemab-Irmb) Supplemental Biologics License Application Regarding Subcutaneous Starting Dose Granted Priority Review by the US FDA

Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®? (Lecanemab)

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review

Eisai Announces Biologics License Application for the Subcutaneous Formulation of Leqembi (Lecanemab) for Treatment of Early Alzheimer's Disease

Eisai Presents the Latest Findings on Time Savings with Continued Treatment with Leqembi

Eisai Co., Ltd. Presents New Data on Anti-Tau Antibody Etalanetug (E2814) At CTAD 2025

Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting Dose

Eisai Co., Ltd. Completes Rolling Submission to U.S. FDA for Leqembi®? Iqlik™? (Lecanemab-Irmb) Supplemental Biologics License Application as A Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

BioArctic AB's (publ) Partner Eisai to Present the Latest Findings on Lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease Conference

Eisai Announces Leqembi Approval for IV Maintenance Treatment in the United Kingdom

Eisai Co., Ltd. Enters into Settlement Agreement with Torrent Pharmaceuticals Ltd

Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Cancer

Merck and Eisai Announces Phase 3 LITESPARK-011 Trial Evaluating the Dual Oral Regimen of LENVIMA

Health Canada Grants Authorization for Leqembi (Lecanemab)

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Eisai Co., Ltd. and Biogen Inc. Announce U.S. Availability of Leqemab-irmb Subcutaneous Injection Main Maintenance Dose for Treatment of Early Alzheimer's Disease

Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study

Eisai Announces Leqembi Approval for IV Maintenance Treatment in China

Eisai Co., Ltd. and Biogen Inc. Announces Therapeutic Goods Administration Approves for the Treatment of Alzheimer's Disease in Australia

Eisai Co., Ltd. Announces Etalanetug Granted FDA Fast Track Designation

Eisai Co., Ltd. Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

Eisai Co., Ltd. to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

Eisai Co., Ltd. Initiates Rolling Submission of Supplemental Biologics License Application to U.S. Food and Drug Administration for lecanemab-irmb Subcutaneous Autoinjector (SC-AI), LEQEMBI IQLIK

Eisai Announces US FDA Approval of Leqembi IQKLIK®? (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announce That the Anti-Amyloid Beta (Ab) Monoclonal Antibody "LEQEMBI" Has Been Launched in Austria on August 25, 2025 and Will Be Launched in Germany on September 1, 2025

Eisai Presents Latest Findings on Lecanemab (Leqembi) At the Alzheimer's Association International Conference

Eisai and Biogen Present Results on Lecanemab Subcutaneous Autoinjector At AAIC 2025

PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib Mesylate

Eisai Co., Ltd., Annual General Meeting, Jun 18, 2025

Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.

MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UK

Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European Union

Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025

Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Announces FDA Approval for Leqembi in US

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai Launches Leqembi in South Korea

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Second quarter 2025 earnings released: EPS: JP¥39.19 (vs JP¥9.73 in 2Q 2024)

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Upcoming dividend of JP¥80.00 per share

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: JP¥36.95 (vs JP¥70.92 in 1Q 2024)

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Final dividend of JP¥80.00 announced